European experience of cladribine tablets in elderly patients with multiple sclerosis: Could it be the last treatment?

Date publication

mars 2025

Journal

Multiple sclerosis journal - experimental, translational and clinical

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
de Seze J, Zecca C, Castelnovo G, Ayrignac X, Vermersch P, Gobbi C, Mallucci G, Carra-Dallière C, Labauge P, Bigaut K, Kremer L, Collongues N, Lanotte L, Thouvenot E, Ernon C, Dive D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40104668

Résumé

Recent studies support the need for early and intensive disease-modifying treatment (DMT) for patients with multiple sclerosis (PWMS). Abrupt DMT withdrawal may risk disease reactivation. Recent studies showed that MS disease activity was not rare after DMT withdrawal for PWMS aged >45/55 y. Immune reconstitution therapy (IRT) with cladribine tablets (CladT), may be an option for older PWMS who wish to stop DMT.

Mots clés

cladribine, exit therapy, multiple sclerosis

Référence

Mult Scler J Exp Transl Clin. 2025 03 17;11(1):20552173251321810